Evaxion
Business Services · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
F Dr Neergaards Vej 5, Hoersholm, North ...Phone Number
+45 31319753Website
www.evaxion.aiRevenue
$7.5 MillionStock Symbol
EVAXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Evaxion
Evaxion Biotech is a pioneering TechBio company that utilizes its advanced AI platform, AI-Immunology, to discover, design, and develop personalized vaccines for cancer and infectious diseases. The company focuses on decoding the human immune system to create novel vaccine candidates tailored to specific disease signatures. With a multidisciplinary team and state-of-the-art facilities, Evaxion aims to rapidly identify therapeutically relevant vaccine targets, enhancing the efficiency of vaccine development. Their innovative approach positions them at the forefront of the biotechnology industry, addressing the growing demand for effective treatments against critical diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Evaxion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Evaxion has recently received funding, and reach out quickly before it becomes old news!
Click to see if Evaxion had a recent Job posting/layoffs
Evaxion, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Evaxion launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Evaxion has new funding data
Earning: See what the market has to say on Evaxion recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Evaxion
Check out if Evaxion is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Evaxion is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Evaxion is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Evaxion.
Evaxion financials insights
Gather financial insights about Evaxion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Private Equity
$40M
Evaxion Tech Stack
A closer look at the technologies used by Evaxion
See more technologies
Most Recent Scoops
Promotion
Executive Move
Birgitte Rønø, Chief Scientific Officer, has assumed the additional role of Chief Operating Officer.
Executive Moves, Promotion
Project
reported two-year Phase 2 data for EVX-01, its personalized peptide-based cancer vaccine in advanced melanoma, presented at ESMO in October. The data showed a 75% objective response rate, 25% complete response rate, and 92% of responders remained in response at the two-year mark.
Medical Research, Pharmaceuticals, Clinical Operations
Partnership
Evaxion Biotech has entered into a collaboration with The Gates Foundation on the design of a new polio vaccine. The company reports significant interest in its platform and pipeline programs from multiple parties.
Partnership, Product Development, Pharmaceuticals
Award
Evaxion Biotech has been recognized by The Galien Foundation for AI advances in human health. This recognition honors the company's AI-Immunology platform.
Award, Artificial Intelligence
Project
Pharmaceuticals, Artificial Intelligence
Evaxion News & Media
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new preclinical data for vaccine candidate EVX-V1 in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15, 2026.Evaxion receives Prix Galien UK Award for Best digital health solution
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Evaxion
Sign Up For FreeTo access detailed company insights
Evaxion Biotech is a pioneering TechBio company that utilizes its advanced AI platform, AI-Immunology, to discover, design, and develop personalized vaccines for cancer and infectious diseases. The company focuses on decoding the human immune system to create novel vaccine candidates tailored to specific disease signatures. With a multidisciplinary... Read More
